Redeye argues that Safeture’s Q4 2022 report was rather undramatic, although it was hit by a one-time customer write-off. The ARR and net sales grew close to the company’s financial target, and the scaling was still showing. We believe the company will continue to take clear steps toward profitability in 2023 and expand its partner network.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/